Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)
See the rest here:
Latisse Faces Patent Challenge
Long Lashes Without Prescription, but With Risks
A glaucoma eyedrop, reinvented, is routinely available without a doctor’s prescription or visit. (Source: NYT Health)
Originally posted here:
Long Lashes Without Prescription, but With Risks
Latisse lash lengthener has its fans and detractors
Many users swear by its effectiveness, but the drug, developed to treat glaucoma, can have unpleasant side effects.
View original post here:
Latisse lash lengthener has its fans and detractors
FDA: Allergan’s Web Site Is Misleading
The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven. (Source: WSJ.com: Health)
View post:
FDA: Allergan’s Web Site Is Misleading
Chance side effect creates thick eyelashes, market for Latisse
Another drug is getting a second life because of desirable side effects. (Source: USATODAY.com Health)
Continued here:
Chance side effect creates thick eyelashes, market for Latisse
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Reuters Health Information (Source: Medscape Medical News Headlines)
Read the original post:
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Originally posted here:
Allergan Eyelash Enhancer Approved
